Medico Remedies

Who are the top shareholders of the Medico Remedies?

The top shareholders of Medico Remedies include Haresh Kapurlal Mehta with 20.76%, followed by public shareholder Ravi Goyal Huf at 6.84%. Individual investors hold a combined 22.13%, and there are no pledged promoter holdings.

The top shareholders of Medico Remedies include the promoters, with Haresh Kapurlal Mehta holding the highest stake at 20.76%. Additionally, the highest public shareholder is Ravi Goyal Huf, who owns 6.84%. The company also has individual investors holding a combined 22.13%. There are no pledged promoter holdings, and the company is held by six foreign institutional investors, accounting for 0.12%.

how big is Medico Remedies?

As of Jun 06, Medico Remedies Ltd has a market capitalization of 432.00 Cr, classifying it as a Micro Cap company, with net sales of 150.94 Cr and a net profit of 10.09 Cr reported for the latest four quarters. Shareholder's Funds are 52.37 Cr and Total Assets amount to 96.20 Cr as of Mar'24.

Market Cap: As of Jun 06, Medico Remedies Ltd has a market capitalization of 432.00 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The company reported net sales of 150.94 Cr and a net profit of 10.09 Cr for the latest four quarters, which is based on Standalone data.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the latest annual period ending in Mar'24. Shareholder's Funds are reported at 52.37 Cr, while Total Assets amount to 96.20 Cr.

What does Medico Remedies do?

Medico Remedies Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, incorporated in 1994 and publicly listed since 2017, with recent quarterly net sales of 41 Cr and net profit of 4 Cr as of March 2025. Key financial metrics include a market cap of Rs 432 Cr, P/E of 44.00, and a return on equity of 16.15%.

Overview: <BR>Medico Remedies Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>Medico Remedies Limited was incorporated as a Private Limited Company in 1994 and later changed its status to a Public Limited Company on March 6, 2017. The most recent quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>- Net Sales: 41 Cr (Quarterly Results - Mar 2025) <BR>- Net Profit: 4 Cr (Quarterly Results - Mar 2025) <BR>- Market Cap: Rs 432 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>- P/E: 44.00 <BR>- Industry P/E: 35 <BR>- Dividend Yield: 0.00% <BR>- Debt Equity: 0.19 <BR>- Return on Equity: 16.15% <BR>- Price to Book: 7.04 <BR><BR>Contact Details: <BR>Address: 1105/1106 11-Flr Hubtown Solar, N S Phadke Marg Andheri East Mumbai Maharashtra : 400069 <BR>Tel: 91-22-2670 1055/66 <BR>Email: info@medicoremedies.com <BR>Website: http://www.medicoremedies.com

What is the bonus history of the Medico Remedies?

Medico Remedies issued a significant bonus in a 3:1 ratio, with an ex-date of November 16, 2021, and a record date of November 17, 2021, meaning shareholders received three additional shares for each share held.

Medico Remedies has a bonus history that includes a significant bonus issue announced as a 3:1 ratio. This bonus was issued with an ex-date of November 16, 2021, and the record date was November 17, 2021. This means that for every one share held, shareholders received three additional shares. If you have any more questions about Medico Remedies or need further details, feel free to ask!

Has Medico Remedies declared dividend?

No Dividend History Available

Who are the peers of the Medico Remedies?

Peers of Medico Remedies include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. Medico Remedies has average management risk and growth, with a 1-year return of 42.65%, lower than Divi's Lab's 51.96% but higher than Valiant Laborato's -25.23%.

Peers: The peers of Medico Remedies are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Valiant Laborato, Brooks Lab., Zim Laboratories, Lyka Labs, and Infinium Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Lyka Labs, while Good management risk is found at Divi's Lab., Torrent Pharma, and Infinium Pharma. Average management risk is present at Medico Remedies and Zim Laboratories, while Below Average management risk is noted at Valiant Laborato and Brooks Lab. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Average growth is seen at Medico Remedies and Lyka Labs. Below Average growth is noted at Divi's Lab., Torrent Pharma, Valiant Laborato, Brooks Lab., and Zim Laboratories. Excellent capital structure is found at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Good capital structure is present at Medico Remedies and Average capital structure is noted at Zim Laboratories. Below Average capital structure is observed at Valiant Laborato, Brooks Lab., and Lyka Labs.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.96%, while the peer with the lowest is Valiant Laborato at -25.23%. Medico Remedies has a 1-year return of 42.65%, which is significantly higher than Valiant Laborato but lower than Divi's Lab. Additionally, Zim Laboratories and Valiant Laborato have negative six-month returns.

What is the technical trend for Medico Remedies?

As of June 2, 2025, Medico Remedies is in a bearish trend with moderate strength, driven by bearish signals from key indicators like the MACD, Bollinger Bands, and moving averages, despite some bullish signals from the OBV.

As of 2 June 2025, the technical trend for Medico Remedies has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this assessment include the weekly MACD and Bollinger Bands both signaling bearish trends, alongside daily moving averages also indicating bearish momentum. The KST is bearish on a weekly basis and mildly bearish on a monthly basis, while the Dow Theory reflects a mildly bearish stance on the weekly and monthly charts. Despite the OBV showing bullish signals on both weekly and monthly time frames, the overall technical picture remains bearish.

Who are in the management team of Medico Remedies?

As of March 2023, the management team of Medico Remedies includes Haresh Mehta (Chairman & Wholetime Director), Harshit Mehta (Managing Director), Rita Mehta (Director), Rishit Mehta (Whole-time Director), and several independent directors: Deepak Vekaria, Ramesh Rughani, Bharat Rathod, and Deepesh Shah, along with Dinesh Modi (Company Secretary & Compliance Officer).

As of March 2023, the management team of Medico Remedies includes the following individuals:<BR><BR>1. Haresh Mehta - Chairman & Wholetime Director<BR>2. Harshit Mehta - Managing Director<BR>3. Rita Mehta - Director<BR>4. Rishit Mehta - Whole-time Director<BR>5. Deepak Vekaria - Independent Director<BR>6. Ramesh Rughani - Independent Director<BR>7. Bharat Rathod - Independent Director<BR>8. Dinesh Modi - Company Secretary & Compliance Officer<BR>9. Deepesh Shah - Independent Director<BR><BR>These individuals play various roles within the company's leadership structure.

Is Medico Remedies overvalued or undervalued?

As of November 27, 2025, Medico Remedies is considered overvalued with a PE ratio of 37.29, a Price to Book Value of 6.33, and an EV to EBITDA of 28.31, indicating high valuations relative to earnings and assets, despite having a lower PE than Sun Pharma and a higher PEG ratio of 0.78 compared to its peers.

As of 27 November 2025, Medico Remedies has moved from a fair to an expensive valuation grade. The company appears overvalued based on its current financial metrics. The PE ratio stands at 37.29, while the Price to Book Value is 6.33, and the EV to EBITDA is 28.31, indicating a high valuation relative to its earnings and assets.<BR><BR>In comparison to its peers, Medico Remedies' PE ratio is slightly lower than Sun Pharma's 37.62 but significantly higher than Cipla's attractive PE of 22.67. Additionally, the PEG ratio of 0.78 suggests that while the company may have growth potential, its current price does not reflect a favorable valuation compared to its earnings growth. Recent stock performance shows that while Medico Remedies has outperformed the Sensex over the past year, it has lagged behind in the year-to-date comparison, reinforcing the notion that the stock may be overvalued at this time.

How has been the historical performance of Medico Remedies?

Medico Remedies has shown consistent growth in net sales and profits, with net sales increasing from 121.02 Cr in Mar'22 to 150.94 Cr in Mar'25, and operating profit rising from 7.21 Cr to 15.00 Cr during the same period. The company's total assets also expanded significantly, reflecting a robust financial performance.

Answer:<BR>The historical performance of Medico Remedies shows a consistent growth trend in net sales and profits over the years, with significant improvements in various financial metrics.<BR><BR>Breakdown:<BR>Medico Remedies has demonstrated a steady increase in net sales, rising from 121.02 Cr in Mar'22 to 150.94 Cr in Mar'25. This growth is reflected in total operating income, which also increased from 121.02 Cr in Mar'22 to 150.94 Cr in Mar'25. The raw material cost has similarly risen, from 84.67 Cr in Mar'22 to 111.39 Cr in Mar'25, while total expenditure has grown from 113.81 Cr in Mar'22 to 135.94 Cr in Mar'25. Operating profit, excluding other income, has improved significantly from 7.21 Cr in Mar'22 to 15.00 Cr in Mar'25, contributing to an operating profit margin that increased from 5.96% to 9.94% over the same period. Profit before tax has also shown a positive trend, climbing from 6.55 Cr in Mar'22 to 13.50 Cr in Mar'25, with profit after tax following suit from 4.89 Cr to 10.09 Cr. The company's total assets have expanded from 77.22 Cr in Mar'22 to 119.55 Cr in Mar'25, while total liabilities have increased from 77.22 Cr to 119.55 Cr during the same timeframe. Cash flow from operating activities has fluctuated, showing a cash inflow of 2.00 Cr in Mar'24 after a previous high of 8.00 Cr in Mar'23. Overall, Medico Remedies has shown a robust financial performance with increasing revenues and profits, alongside a growing asset base.

When is the next results date for Medico Remedies Ltd?

The next results date for Medico Remedies Ltd is 12 February 2026.

The next results date for Medico Remedies Ltd is scheduled for 12 February 2026.

Are Medico Remedies Ltd latest results good or bad?

Medico Remedies Ltd's latest results show strong revenue growth of 48.59% year-on-year, reaching ₹58.68 crores, and a net profit increase of 11.67%. However, declining operating and PAT margins raise concerns about profitability, indicating potential challenges in cost management despite the impressive sales growth.

Medico Remedies Ltd's latest results present a mixed picture. On the positive side, the company achieved a remarkable revenue growth of 48.59% year-on-year, with net sales reaching ₹58.68 crores in Q3 FY26. This growth is indicative of strong market traction and an expanding presence in the competitive pharmaceutical landscape. Additionally, net profit increased by 11.67% quarter-on-quarter and 9.54% year-on-year, totaling ₹2.87 crores.<BR><BR>However, there are significant concerns regarding profitability. The operating margin, excluding other income, declined to 7.38% from 7.88% in the previous year, and the PAT margin fell sharply to 4.89% from 6.63% year-on-year. This indicates that while the company is growing its revenue, it is struggling to maintain profitability, raising questions about cost management and pricing power.<BR><BR>Overall, while the revenue growth is impressive, the deterioration in margins suggests that the company may be sacrificing profitability for market share. Investors should monitor how Medico Remedies addresses these margin pressures in the upcoming quarters to determine the sustainability of its growth strategy.

Which are the latest news on Medico Remedies?

Should I buy, sell or hold Medico Remedies Ltd?

Why is Medico Remedies Ltd falling/rising?

As of 28-Apr, Medico Remedies Ltd's stock price is declining, with a 1.36% drop and significant underperformance compared to its sector and benchmarks. Despite strong management efficiency and profit growth, the stock has seen a year-to-date decline of 19.52% and a notable decrease in investor participation.

As of 28-Apr, Medico Remedies Ltd's stock price is currently falling, as indicated by a change of -0.56, which represents a decline of 1.36%. The stock has underperformed its sector by 0.97% today and has shown a negative trend over various time periods, including a year-to-date decline of 19.52% and a one-year drop of 26.02%. <BR><BR>Despite the company demonstrating strong management efficiency with a high return on capital employed (ROCE) of 15.04% and positive financial results over the last four consecutive quarters, the stock's performance has been below par in both the long term and near term. The stock has also significantly underperformed the BSE500 index over the last three years, one year, and three months. <BR><BR>Additionally, there has been a notable decrease in investor participation, with delivery volume falling by 50.1% against the five-day average. Although the stock is trading at a discount compared to its peers and has shown profit growth of 31.1% over the past year, the overall negative returns and underperformance relative to benchmarks contribute to the current decline in stock price.